Search

Reset

Searching with a thematic focus on Trade Policy

Showing 3691-3700 of 3822 results

Pages

  • Document

    Botswana's trade agreements

    Botswana Institute For Development Policy Analysis, 2000
    This briefing examines the recent changes in Botswana's external trading environment and the consequent challenges. It focusses on the different trading agreements relevant to Botswana and their implications.
  • Document

    Trade liberalisation and the clothing and textile industry in Malawi

    Development Policy Research Unit, University of Cape Town (UCT), South Africa, 2001
    The paper provides an overview of the the textile and clothing industry in Malawi and explores the potential implications of three liberalisation agreements: the WTO agreement on clothing and textilesthe SADC trade protocol the COMESA Free Trade Area agreementConclusions include the following:As one of the least developed countries, the WTO agreement will eventually
  • Document

    WTO patent rules and access to medicines: the pressure mounts

    Oxfam, 2001
    Oxfam is calling for TRIPS to be reformed so that developing country governments have the unambiguous right to obtain the cheapest possible life-saving medicines without facing the threats of legal challenges or trade sanctions experienced by South Africa and Brazil.
  • Document

    The use of proprietary biotechnology research inputs at selected Latin American NAROs

    International Service for National Agricultural Research, 2000
    The main purpose of this Briefing Paper is to provide an assessment of the use of proprietary biotechnology inputs in the agricultural research systems of selected Latin American countries: Brazil, Chile, Colombia, Costa Rica, and Mexico.
  • Document

    World Trade Organisation agreements: implications for equity and health in Southern Africa

    EQUINET: Network for Equity in Health in Southern Africa, 2000
    This paper investigates the consequences of WTO agreements relating to health, and primarily the TRIPS agreement on health care and drug access for Southern African Development Community (SADC) countries.The paper provides a brief review of GATT /WTO and WTO agreements relating to health.
  • Document

    Communication from the European Communities and their Member States to the TRIPS council: the relationship between provisions of the TRIPS agreement and access to medicines

    European Union, 2001
    Paper comes in response to The EC and their Member States recognition of the lack of affordable pharmaceuticals as a serious problem in many developing countries and especially for the poorest people.Paper assesses: relevance of intellectual property; compulsory licensing; exceptions to patent rights; and, protection of undisclosed informationSummary and recommendations:The spirall
  • Document

    Sugar policy and reform

    World Bank, 2001
    This article discusses the issue of interventions into sugar markets.
  • Document

    Increasing access to health care in developing countries: the need for public-private partnership

    International Federation of Pharmaceutical Manufacturers Associations, 2000
    When problems of access to novel or even older treatments are discussed, many reasons are cited – including financial, infrastructure, and cost factors.Conclusion: It is clear that price plays a less important role than infrastructure, financing and national political will in ensuring access to drugs, particularly in developing countries.
  • Document

    Globalisation, privatisation and healthcare: a preliminary report

    Public Services International Research Unit, PSIRU, 2001
    The paper discusses the effects that globalisation and privatisation may have on public health care systems. Threats to public health care include:the WTO provides two kinds of threat to health services. The first is the potential threat of GATS, which could force more privatisation in future.
  • Document

    Encouragement of new clinical drug development: the role of data exclusivity

    International Federation of Pharmaceutical Manufacturers Associations, 2000
    Paper asserts that for the pharmaceutical industry to invest the billions of dollars, Euros, yen, etc. in these highly risky health care solutions, intellectual property protection is essential. However, patent and trade-mark protections are not the entire story.

Pages